The latest from CDMOs, CMOs, and suppliers featuring Granules, Senn Chemicals and Sai Life Sciences.  

Chemicals/Chemical API Manufacturing 
* Granules To Acquire Swiss Peptide CDMO Senn Chemicals 
* Sai Life Sciences Completes IPO 

---

Chemicals/Chemical API Manufacturing 

Granules To Acquire Swiss Peptide CDMO Senn Chemicals 
Granules India, a Hyderabad, India-based pharmaceutical manufacturing company, has agreed to acquire Senn Chemicals, a Dielsdorf, Switzerland-based CDMO specializing in peptides.  

Senn Chemicals provides contract research, development, and manufacturing services with a speciality in custom peptide manufacturing through both liquid-phase peptide synthesis and solid-phase peptide synthesis. It provides development and manufacturing services for peptides, peptide fragments, and amino acid derivatives (AAD). Its cGMP and non-GMP manufacturing capabilities cover new chemical entities for clinical trials, kilo-scale production of cosmetic peptides, and AADs at commercial scale.   

Granules produces active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosage forms. Granules has 10 manufacturing facilities globally, eight in India and two in the US. The acquisition of Senn Chemicals would provide the company with an European presence. 

In addition, Granules says the acquisition aligns with its strategy to enter the peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based APIs, and the companies say that both projects are progressing, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn’s R&D capabilities.  

The closing of the acquisition is subject to certain conditions and is expected to occur in the first half of 2025.  

Source: Granules 

---

Sai Life Sciences Completes IPO 
Sai Life Sciences, a contract research organization and a CDMO of small-molecule active pharmaceutical ingredients (APIs) and intermediates, reported last month (January 29, 2025) that it had successfully completed a $366-million initial public offering on the National Stock Exchange of India Limited, which also included an offer of sale by private-equity investors.  

The company had launched the IPO in late December (December 2024). The company, headquartered in Telangana, India, has over 3,000 employees across its R&D and manufacturing sites in India, the UK, and the US. 

Source: SAI Life Sciences